A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

Trial Details

NCT ID
NCT05123482
Phase
PHASE1 / PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • AZD8205
  • AZD8205 and AZD2936 (Rilvegostomig)
  • AZD8205 and AZD5305 (saruparib)
  • AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)
  • AZD8205 in combination with AZD9574
  • AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Santa Monica, California, United States|34.01949,-118.49138
  • Shreveport, Louisiana, United States|32.52515,-93.75018
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Age ≥ 18 years
  • Relapsed/metastatic solid tumors treated with prior adequate standard of care therapy for tumor type and stage of disease or where in the opinion o…
  • Measurable disease per RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →